Natural Immunomodulators: Promising Therapy for Disease Management discusses the use of natural immunomodulators as a promising therapy for managing various diseases. The book begins with an introduction to the immune system and the ways in which it can be modulated. This is followed by a discussion on the various diseases and disorders associated with the immune system, including autoimmune disorders, allergies, and immune deficiency conditions. The natural sources of immunomodulators, including plants, herbs, and other natural substances is also explained along with the importance of standardizing natural immunomodulator drugs, including the methods used to ensure their quality and consistency. The book also delves into the chemistry and analytical techniques used to study immunomodulators, clinical and pre-clinical bioassays. The next couple of chapters focus on the use of natural immunomodulators in cancer, the therapy of cancer and infectious diseases. Drug delivery and the strategy and regulatory perspective for natural immunomodulators. The final 2 chapters round up the contents with information about synthetic immunomodulators and the future perspective for the use of immunomodulators in disease management. Natural Immunomodulators: Promising Therapy for Disease Management is a comprehensive guide to the use of natural immunomodulators as a therapy for various diseases, and is a valuable resource for professionals and students interested in this topic. The book is aimed at health care professionals such as medical doctors, nurses, pharmacists, and life science and nutritionist professionals, as well as students.

Humans coexist with millions of harmless microorganisms, but emerging diseases, resistance to antibiotics, and the threat of bioterrorism are forcing scientists to look for new ways to confront the microbes that do pose a danger. This report identifies innovative approaches to the development of antimicrobial drugs and vaccines based on a greater understanding of how the human immune system interacts with both good and bad microbes. The report concludes that the development of a single superdrug to fight all infectious agents is unrealistic.

Much has been written about food allergies in scientific journals and in the lay press, but Food Allergies: Processing Technologies for Allergenicity Reduction approaches the issue of food allergies from an industrial processing rather than a clinical perspective. Indeed, industrial food processing technologies can have many beneficial effects to obtain various food products and to preserve foods from physical, chemical and microbiological alterations. However, processing technologies, including thermal and non‐thermal technologies, can also alter the allergenic properties of food proteins. This book provides an authoritative source of information on the relationship between food processing technologies and food allergens with a greater variety of studied allergens including peanuts, tree nuts, cow’s milk, eggs, sesame, lupine, soy, wheat, mustard, mushroom, fish and shellfish, as well as the importance of processing these when producing hypoallergenic foods. Key Features: Presents food allergies with recent advances and statistics concerning prevalence, physiopathologic mechanism, diagnosis and anaphylaxis Discusses food allergies in the food industry and investigates the effect of processing on allergenicity of foods during manufacturing Provides food processing and promising technologies to produce hypoallergenic food with high quality Covers the allergenic effect of different food additives with an investigation of cross‐reaction risks This unique book is an indispensable guide for allergic patients, production managers, scientists and nutritionists within the food industry as well as covering a range of critical topics in this area for all those concerned with understanding and managing food allergies.

This book will cover both the evidence for biofilms in many chronic bacterial infections as well as the problems facing these infections such as diagnostics and treatment regimes. A still increasing interest and emphasis on the sessile bacterial lifestyle biofilms has been seen since it was realized that that less than 0.1% of the total microbial biomass lives in the planktonic mode of growth. The term was coined in 1978 by Costerton et al. who defined the term biofilm for the first time.In 1993 the American Society for Microbiology (ASM) recognised that the biofilmmode of growth was relevant to microbiology. Lately many articles have been published on the clinical implications of bacterial biofilms. Both original articles and reviews concerning the biofilm problem are available.

Herbal Biomolecules in Healthcare Applications presents extensive detailed information on all the vital principles, basics and fundamental aspects of multiple herbal biomolecules in the healthcare industry. This book examines important herbal biomolecules including alkaloids, glycosides, flavonoids, anthraquinones, steroids, polysaccharides, tannins and polyphenolic compounds, terpenes, fats and waxes, proteins and peptides, and vitamins. These herbal biomacromolecules are responsible for different bioactivities as well as pharmacological potentials. A systematic understanding of the extraction, purification, characterization, applications of these herbal biomolecules and their derivatives in healthcare fields is developed in this comprehensive book. Chapters explore the key topics along with an emphasis on recent research and developments in healthcare fields by leading experts. They include updated literature review of the relevant key topics, good quality illustrations, chemical structures, flow charts, well-organized tables and case studies. Herbal Biomolecules in Healthcare Applications will be useful for researchers working on natural products and biomolecules with bioactivity and nutraceutical properties. Professionals specializing in scientific areas such as biochemistry, pharmacology, analytical chemistry, organic chemistry, clinics, or engineering focused on bioactive natural products will find this book useful. - Provides a study of different type of biomolecules from herbal extracts and their bioactivities as well as their application in the healthcare industry - Contributions by global leaders and experts from academia, industry and regulatory agencies, who have been considered as pioneers in the application of herbal biomolecules in the diverse healthcare fields - Includes updated literature review along with practical examples and research case studies

The herbai medicine industry is growing at an astounding rate. Trade group estimates suggest that total sales exceeded $4 billion dollars in 1999. Herbai remedies are for sale not just in health food stores, but in supermar kets, drug stores, and even discount warehouses. Along with the proliferation in sales has come a proliferation ofinformation sources. Not all ofthe sources are equally reliable, or even intelligible. Traditional herbalists c1assify thistle and mugwort as "cholagogues," substances used to make the gallbladder con tract and release bile. Medical school graduates are unlikely to have ever heard the term, or even accept the notion that most right-sided abdominal pain is a result of diminished bile flow. Heroin and cocaine may not be the only drugs to come from plants, but a practicing physician or toxicologist might be forgiven for thinking so. In 1998, 1264 papers were published about cocaine and only 17 about kava kava, an abused herb that is not without toxic side effects. Unfortunately, the majority of the papers about kava kava were published in journals not found in ordi nary hospitallibraries. In recognition ofthis fact, and ofthe obvious need for a reliable reference work on herbai toxicology, The Toxicology and Clinical Pharmacology 0/ Herbal Products was an early addition to our new series in Forensie Science and Medicine. It is very badly needed.

This book is a printed edition of the Special Issue "Mind-Body Medicine in Children and Adolescents" that was published in Children

Immunotherapy is a form of cancer therapy that harnesses the body's immune system to destroy cancer cells. In recent years, immunotherapies have been developed for several cancers, including advanced melanoma, lung cancer, and kidney cancer. In some patients with metastatic cancers who have not responded well to other treatments, immunotherapy treatment has resulted in complete and durable responses. Given these promising findings, it is hoped that continued immunotherapy research and development will produce better cancer treatments that improve patient outcomes. With this promise, however, there is also recognition that the clinical and biological landscape for immunotherapies is novel and not yet well understood. For example, adverse events with immunotherapy treatment are quite different from those experienced with other types of cancer therapy. Similarly, immunotherapy dosing, therapeutic responses, and response time lines are also markedly different from other cancer therapies. To examine these challenges and explore strategies to overcome them, the National Academies of Sciences, Engineering, and Medicine held a workshop in February and March of 2016. This report summarizes the presentations and discussions from the workshop.

This report is structured in five parts: national framework for traditional and complementary medicine (T&CM); product regulation; practices and practitioners; the challenges faced by countries; and finally the country profiles. Apart from the section on practices and practitioners the report is consistent with the format of the report of the first global survey in order to provide a useful comparison. The section on practices and practitioners which covers providers education and health insurance is a new section incorporated to reflect the emerging trends in T&CM and to gather new information regarding these topics at a national level. All new information received has been incorporated into individual country profiles and data graphs. The report captures the three phases of progress made by Member States; that is before and after the first WHO Traditional Medicine Strategy (1999?2005) from the first global survey to the second global survey (2005?2012) and from the second survey to the most recent timeline (2012?2018).